<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="GBP" hierarchy="1" humanitarian="0" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>GB-EDU-133784-BactiVac-MR/R005974/1</iati-identifier>
  <reporting-org ref="GB-EDU-133784" type="80">
   <narrative xml:lang="EN">University of Birmingham</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Bacterial Vaccines (BactiVac) Network</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="EN">BactiVac is a global bacterial vaccinology network bringing together members based in academic, industry and policy sectors to accelerate the development of vaccines against bacterial infections relevant to low and middle-income countries (LMICs). The BactiVac Network will deliver this through catalyst project and training awards to encourage cross-collaboration between academic and industrial partners in developed and developing nations.</narrative>
  </description>
  <participating-org role="1" type="60">
   <narrative xml:lang="EN">Bill &amp; Melinda Gates Foundation (BMGF)</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">Department of Health and Social Care (DHSC)</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">Industry Strategy Challenge Fund (ISCF)</narrative>
  </participating-org>
  <participating-org role="1" type="80">
   <narrative xml:lang="EN">Institute for Global Innovation, University of Birmingham</narrative>
  </participating-org>
  <participating-org role="1" type="10">
   <narrative xml:lang="EN">UKRI Medical Research Council (MRC)</narrative>
  </participating-org>
  <participating-org role="4" type="80">
   <narrative xml:lang="EN">University of Birmingham</narrative>
  </participating-org>
  <activity-status code="2"></activity-status>
  <activity-date iso-date="2017-08-14" type="2"></activity-date>
  <activity-date iso-date="2022-08-13" type="4"></activity-date>
  <recipient-country code="GB" percentage="100"></recipient-country>
  <sector code="11420" percentage="100" vocabulary="1"></sector>
  <sector code="12182" percentage="100" vocabulary="1"></sector>
  <sector code="12250" percentage="100" vocabulary="1"></sector>
  <sector code="43082" percentage="100" vocabulary="1"></sector>
  <budget status="2" type="1">
   <period-start iso-date="2017-08-14"></period-start>
   <period-end iso-date="2018-08-13"></period-end>
   <value currency="GBP" value-date="2020-12-08">546541</value>
  </budget>
  <budget status="2" type="1">
   <period-start iso-date="2018-08-14"></period-start>
   <period-end iso-date="2019-08-13"></period-end>
   <value currency="GBP" value-date="2020-12-08">400000</value>
  </budget>
  <budget status="2" type="1">
   <period-start iso-date="2018-08-14"></period-start>
   <period-end iso-date="2019-08-13"></period-end>
   <value currency="GBP" value-date="2020-12-08">546541</value>
  </budget>
  <budget status="2" type="1">
   <period-start iso-date="2018-08-14"></period-start>
   <period-end iso-date="2019-08-13"></period-end>
   <value currency="GBP" value-date="2020-12-08">600000</value>
  </budget>
  <budget status="2" type="1">
   <period-start iso-date="2019-08-14"></period-start>
   <period-end iso-date="2020-08-13"></period-end>
   <value currency="GBP" value-date="2020-12-08">546541</value>
  </budget>
  <budget status="2" type="1">
   <period-start iso-date="2019-08-14"></period-start>
   <period-end iso-date="2020-08-13"></period-end>
   <value currency="GBP" value-date="2020-12-08">600000</value>
  </budget>
  <budget status="2" type="2">
   <period-start iso-date="2020-04-01"></period-start>
   <period-end iso-date="2021-03-31"></period-end>
   <value currency="GBP" value-date="2021-06-15">-44900</value>
  </budget>
  <budget status="2" type="2">
   <period-start iso-date="2020-08-14"></period-start>
   <period-end iso-date="2021-08-13"></period-end>
   <value currency="GBP" value-date="2020-11-13">-23673</value>
  </budget>
  <budget status="2" type="1">
   <period-start iso-date="2020-08-14"></period-start>
   <period-end iso-date="2021-08-13"></period-end>
   <value currency="GBP" value-date="2020-12-08">546541</value>
  </budget>
  <transaction ref="BactiVac admin costs - Year 1, 2018/19">
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2019-03-31"></transaction-date>
   <value currency="GBP" value-date="2019-03-31">11214</value>
   <description>
    <narrative xml:lang="EN">BactiVac admin expenditure for year 1, 2018/19</narrative>
   </description>
  </transaction>
  <transaction ref="BactiVac admin costs - Year 2, 2019/20">
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2019-03-31"></transaction-date>
   <value currency="GBP" value-date="2019-03-31">51078</value>
   <description>
    <narrative xml:lang="EN">BactiVac admin expenditure for year 2, 2019/20</narrative>
   </description>
  </transaction>
  <transaction ref="BactiVac admin costs - Year 3, 2020/21">
   <transaction-type code="4"></transaction-type>
   <transaction-date iso-date="2019-03-31"></transaction-date>
   <value currency="GBP" value-date="2019-03-31">30897</value>
   <description>
    <narrative xml:lang="EN">BactiVac admin expenditure for year 3, 2020/21</narrative>
   </description>
  </transaction>
  <transaction ref="Catalyst project BVNCP3-08, &apos;Development of a bivalent vaccine against Acinetobacter baumannii (A. baumannii) and Streptococcus agalactiae (S. agalactiae).&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-12-04"></transaction-date>
   <value currency="GBP" value-date="2019-12-04">25000</value>
   <description>
    <narrative xml:lang="EN">Milestone 1 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">Bio-Manguinhos, Brazil</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP2-09, &apos;Molecular epidemiology of Group A Streptococcus in West Africa (acronym: MEGAS)&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-04-05"></transaction-date>
   <value currency="GBP" value-date="2019-04-05">39998.27</value>
   <description>
    <narrative xml:lang="EN">Milestone 1 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">Disease Control &amp; Elimination, MRC Unit The Gambia at LSHTM</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP3-30, &apos;Targeting AMR via the lymphatic system&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-11-26"></transaction-date>
   <value currency="GBP" value-date="2019-11-26">24343.17</value>
   <description>
    <narrative xml:lang="EN">Milestone 1 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">Imperial College London, UK</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP3-07, &apos;Antigen discovery to accelerate Acinetobacter baumannii vaccine development&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-12-12"></transaction-date>
   <value currency="GBP" value-date="2019-12-12">18658.29</value>
   <description>
    <narrative xml:lang="EN">Milestone 1 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">Imperial College London, UK</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP2-10, &apos;Advancing a native outer membrane vesicle vaccine against gonorrhoea towards clinical development&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-04-08"></transaction-date>
   <value currency="GBP" value-date="2019-04-08">32431.77</value>
   <description>
    <narrative xml:lang="EN">Milestone 1 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">Jenner Institute, University of Oxford, UK</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP2-01, &apos;Towards the production of &#x201C;Shigella plus&#x201D; a low-cost recombinant Shigella glycoconjugate vaccines&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-03-13"></transaction-date>
   <value currency="GBP" value-date="2019-03-13">41993</value>
   <description>
    <narrative xml:lang="EN">Milestone 1 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">London School of Hygiene and Tropical Medicine, UK</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP2-03, &apos;Evaluation of the sublingual route of immunisation for the induction of mucosal and systemic immune responses to  polysaccharide-protein conjugate vaccines&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-04-12"></transaction-date>
   <value currency="GBP" value-date="2019-04-12">25000</value>
   <description>
    <narrative xml:lang="EN">Milestone 1 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">University College London, School of Pharmacy, UK</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP3-24, &apos;SAL-O5_Asses the variation in lipopolysaccharide structure in circulating African invasive Salmonella Typhimurium isolates to predict vaccine coverage&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-12-12"></transaction-date>
   <value currency="GBP" value-date="2019-12-12">17620.87</value>
   <description>
    <narrative xml:lang="EN">Milestone 1 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">University of Antwerp, Belgium</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP2-06, &apos;Developing whole cell vaccines with tailored immunogenicity through combinatorial engineering of lipid A&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-04-02"></transaction-date>
   <value currency="GBP" value-date="2019-04-02">24532</value>
   <description>
    <narrative xml:lang="EN">Milestone 1 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">University of Bath, UK</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP3-34, &apos;Immunizing humanised mice with outer membrane vesicles from Acinetobacter baumannii to study antigen recognition and vaccine development">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-10-31"></transaction-date>
   <value currency="GBP" value-date="2019-10-31">30630.86</value>
   <description>
    <narrative xml:lang="EN">Milestone 1 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">University of Birmingham, UK</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP3-17, &apos;Maternal intranasal vaccination using novel Pneumolysin conjugated vaccines to protect offspring from pneumococcal infection&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-10-30"></transaction-date>
   <value currency="GBP" value-date="2019-10-30">31437.76</value>
   <description>
    <narrative xml:lang="EN">Milestone 1 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">University of Cape Town, SA</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP3-05, &apos;New correlates of protection for an Escherichia coli vaccine&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-11-21"></transaction-date>
   <value currency="GBP" value-date="2019-11-21">24537.07</value>
   <description>
    <narrative xml:lang="EN">Milestone 1 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">University of Leicester, UK</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP2-04, &apos;Development of a novel intranasal vaccine against pneumococcal infection in children&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-04-08"></transaction-date>
   <value currency="GBP" value-date="2019-04-08">25000</value>
   <description>
    <narrative xml:lang="EN">Milestone 1 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">University of Liverpool, UK</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP2-07, &apos;Prevalence and serotype distribution of group B Streptococcus in Le&#xF3;n, Nicaragua&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-04-12"></transaction-date>
   <value currency="GBP" value-date="2019-04-12">24924.8</value>
   <description>
    <narrative xml:lang="EN">Milestone 1 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">University of North Carolina at Chapel Hill, USA</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP3-15, &apos;Towards a bivalent enteric fever vaccine: exploring the potential of a paratyphoid vaccine candidate combined with a typhoid conjugate vaccine&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-12-06"></transaction-date>
   <value currency="GBP" value-date="2019-12-06">23190.01</value>
   <description>
    <narrative xml:lang="EN">Milestone 1 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">University of Oxford, UK</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP2-02, &apos;Optimisation of novel mucosal vaccines to prevent bacterial diseases of Tilapia (Oreochromis niloticus) &apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-03-28"></transaction-date>
   <value currency="GBP" value-date="2019-03-28">24906</value>
   <description>
    <narrative xml:lang="EN">Milestone 1 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">University of Stirling, UK</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP3-32, &apos;Vaccination to break plague transmission in Madagascar&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-11-06"></transaction-date>
   <value currency="GBP" value-date="2019-11-06">23302.5</value>
   <description>
    <narrative xml:lang="EN">Milestone 1 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">University of Strathclyde, UK</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP3-08, &apos;Development of a bivalent vaccine against Acinetobacter baumannii (A. baumannii) and Streptococcus agalactiae (S. agalactiae).&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-04-03"></transaction-date>
   <value currency="GBP" value-date="2020-04-03">15000</value>
   <description>
    <narrative xml:lang="EN">Milestone 2 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">Bio-Manguinhos, Brazil</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP2-09, &apos;Molecular epidemiology of Group A Streptococcus in West Africa (acronym: MEGAS)&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-09-26"></transaction-date>
   <value currency="GBP" value-date="2019-09-26">23998.96</value>
   <description>
    <narrative xml:lang="EN">Milestone 2 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">Disease Control &amp; Elimination, MRC Unit The Gambia at LSHTM</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP3-07, &apos;Antigen discovery to accelerate Acinetobacter baumannii vaccine development&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-12-31"></transaction-date>
   <value currency="GBP" value-date="2019-12-31">11194.97</value>
   <description>
    <narrative xml:lang="EN">Milestone 2 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">Imperial College London, UK</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP3-30, &apos;Targeting AMR via the lymphatic system&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-01-22"></transaction-date>
   <value currency="GBP" value-date="2020-01-22">14605.9</value>
   <description>
    <narrative xml:lang="EN">Milestone 2 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">Imperial College London, UK</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP2-10, &apos;Advancing a native outer membrane vesicle vaccine against gonorrhoea towards clinical development&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-08-08"></transaction-date>
   <value currency="GBP" value-date="2019-08-08">19459.06</value>
   <description>
    <narrative xml:lang="EN">Milestone 2 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">Jenner Institute, University of Oxford, UK</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP2-01, &apos;Towards the production of &#x201C;Shigella plus&#x201D; a low-cost recombinant Shigella glycoconjugate vaccines&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-08-23"></transaction-date>
   <value currency="GBP" value-date="2019-08-23">25195.8</value>
   <description>
    <narrative xml:lang="EN">Milestone 2 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">London School of Hygiene and Tropical Medicine, UK</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP2-03, &apos;Evaluation of the sublingual route of immunisation for the induction of mucosal and systemic immune responses to  polysaccharide-protein conjugate vaccines&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-06-21"></transaction-date>
   <value currency="GBP" value-date="2019-06-21">15000</value>
   <description>
    <narrative xml:lang="EN">Milestone 2 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">University College London, School of Pharmacy, UK</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP3-24, &apos;SAL-O5_Asses the variation in lipopolysaccharide structure in circulating African invasive Salmonella Typhimurium isolates to predict vaccine coverage&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-01-24"></transaction-date>
   <value currency="GBP" value-date="2020-01-24">10572.52</value>
   <description>
    <narrative xml:lang="EN">Milestone 2 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">University of Antwerp, Belgium</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP2-06, &apos;Developing whole cell vaccines with tailored immunogenicity through combinatorial engineering of lipid A&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-06-21"></transaction-date>
   <value currency="GBP" value-date="2019-06-21">14719</value>
   <description>
    <narrative xml:lang="EN">Milestone 2 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">University of Bath, UK</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP3-34, &apos;Immunizing humanised mice with outer membrane vesicles from Acinetobacter baumannii to study antigen recognition and vaccine development">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-02-28"></transaction-date>
   <value currency="GBP" value-date="2020-02-28">18378.52</value>
   <description>
    <narrative xml:lang="EN">Milestone 2 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">University of Birmingham, UK</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP3-17, &apos;Maternal intranasal vaccination using novel Pneumolysin conjugated vaccines to protect offspring from pneumococcal infection&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-02-07"></transaction-date>
   <value currency="GBP" value-date="2020-02-07">18862.66</value>
   <description>
    <narrative xml:lang="EN">Milestone 2 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">University of Cape Town, SA</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP3-05, &apos;New correlates of protection for an Escherichia coli vaccine&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-01-22"></transaction-date>
   <value currency="GBP" value-date="2020-01-22">14722.24</value>
   <description>
    <narrative xml:lang="EN">Milestone 2 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">University of Leicester, UK</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP2-04, &apos;Development of a novel intranasal vaccine against pneumococcal infection in children&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-07-04"></transaction-date>
   <value currency="GBP" value-date="2019-07-04">15000</value>
   <description>
    <narrative xml:lang="EN">Milestone 2 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">University of Liverpool, UK</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP2-07, &apos;Prevalence and serotype distribution of group B Streptococcus in Le&#xF3;n, Nicaragua&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-08-23"></transaction-date>
   <value currency="GBP" value-date="2019-08-23">14954.88</value>
   <description>
    <narrative xml:lang="EN">Milestone 2 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">University of North Carolina at Chapel Hill, USA</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP3-15, &apos;Towards a bivalent enteric fever vaccine: exploring the potential of a paratyphoid vaccine candidate combined with a typhoid conjugate vaccine&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-01-22"></transaction-date>
   <value currency="GBP" value-date="2020-01-22">13914</value>
   <description>
    <narrative xml:lang="EN">Milestone 2 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">University of Oxford, UK</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP2-02, &apos;Optimisation of novel mucosal vaccines to prevent bacterial diseases of Tilapia (Oreochromis niloticus) &apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-07-17"></transaction-date>
   <value currency="GBP" value-date="2019-07-17">14943.6</value>
   <description>
    <narrative xml:lang="EN">Milestone 2 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">University of Stirling, UK</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP3-32, &apos;Vaccination to break plague transmission in Madagascar&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-01-24"></transaction-date>
   <value currency="GBP" value-date="2020-01-24">13981.5</value>
   <description>
    <narrative xml:lang="EN">Milestone 2 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">University of Strathclyde, UK</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP3-08, &apos;Development of a bivalent vaccine against Acinetobacter baumannii (A. baumannii) and Streptococcus agalactiae (S. agalactiae).&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2021-01-31"></transaction-date>
   <value currency="GBP" value-date="2021-01-31">0</value>
   <description>
    <narrative xml:lang="EN">Milestone 3 payment - no further payment due to underspend on project</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">Bio-Manguinhos, Brazil</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP3-07, &apos;Antigen discovery to accelerate Acinetobacter baumannii vaccine development&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-12-31"></transaction-date>
   <value currency="GBP" value-date="2020-12-31">-7835.98</value>
   <description>
    <narrative xml:lang="EN">Milestone 3 payment - reimbursement due to underspend on project</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">Imperial College London, UK</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP2-09, &apos;Molecular epidemiology of Group A Streptococcus in West Africa (acronym: MEGAS)&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-05-05"></transaction-date>
   <value currency="GBP" value-date="2020-05-05">15999.3</value>
   <description>
    <narrative xml:lang="EN">Milestone 3 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">Disease Control &amp; Elimination, MRC Unit The Gambia at LSHTM</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP3-30, &apos;Targeting AMR via the lymphatic system&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-04-08"></transaction-date>
   <value currency="GBP" value-date="2020-04-08">8094.57</value>
   <description>
    <narrative xml:lang="EN">Milestone 3 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">Imperial College London, UK</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP2-10, &apos;Advancing a native outer membrane vesicle vaccine against gonorrhoea towards clinical development&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2021-03-10"></transaction-date>
   <value currency="GBP" value-date="2021-03-10">8311.28</value>
   <description>
    <narrative xml:lang="EN">Milestone 3 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">Jenner Institute, University of Oxford, UK</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP2-03, &apos;Evaluation of the sublingual route of immunisation for the induction of mucosal and systemic immune responses to  polysaccharide-protein conjugate vaccines&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-11-19"></transaction-date>
   <value currency="GBP" value-date="2019-11-19">10000</value>
   <description>
    <narrative xml:lang="EN">Milestone 3 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">University College London, School of Pharmacy, UK</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP2-06, &apos;Developing whole cell vaccines with tailored immunogenicity through combinatorial engineering of lipid A&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-12-17"></transaction-date>
   <value currency="GBP" value-date="2019-12-17">9047.21</value>
   <description>
    <narrative xml:lang="EN">Milestone 3 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">University of Bath, UK</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP3-34, &apos;Immunizing humanised mice with outer membrane vesicles from Acinetobacter baumannii to study antigen recognition and vaccine development">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-10-30"></transaction-date>
   <value currency="GBP" value-date="2020-10-30">12252.35</value>
   <description>
    <narrative xml:lang="EN">Milestone 3 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">University of Birmingham, UK</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP3-17, &apos;Maternal intranasal vaccination using novel Pneumolysin conjugated vaccines to protect offspring from pneumococcal infection&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-12-18"></transaction-date>
   <value currency="GBP" value-date="2020-12-18">12575.1</value>
   <description>
    <narrative xml:lang="EN">Milestone 3 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">University of Cape Town, SA</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP3-05, &apos;New correlates of protection for an Escherichia coli vaccine&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-06-01"></transaction-date>
   <value currency="GBP" value-date="2020-06-01">9814.83</value>
   <description>
    <narrative xml:lang="EN">Milestone 3 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">University of Leicester, UK</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP2-04, &apos;Development of a novel intranasal vaccine against pneumococcal infection in children&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-11-21"></transaction-date>
   <value currency="GBP" value-date="2019-11-21">7057.37</value>
   <description>
    <narrative xml:lang="EN">Milestone 3 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">University of Liverpool, UK</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP2-07, &apos;Prevalence and serotype distribution of group B Streptococcus in Le&#xF3;n, Nicaragua&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2021-02-16"></transaction-date>
   <value currency="GBP" value-date="2021-02-16">9969.92</value>
   <description>
    <narrative xml:lang="EN">Milestone 3 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">University of North Carolina at Chapel Hill, USA</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP3-15, &apos;Towards a bivalent enteric fever vaccine: exploring the potential of a paratyphoid vaccine candidate combined with a typhoid conjugate vaccine&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-10-28"></transaction-date>
   <value currency="GBP" value-date="2020-10-28">7035.54</value>
   <description>
    <narrative xml:lang="EN">Milestone 3 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">University of Oxford, UK</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP2-02, &apos;Optimisation of novel mucosal vaccines to prevent bacterial diseases of Tilapia (Oreochromis niloticus) &apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-02-19"></transaction-date>
   <value currency="GBP" value-date="2020-02-19">8367.38</value>
   <description>
    <narrative xml:lang="EN">Milestone 3 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">University of Stirling, UK</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP3-32, &apos;Vaccination to break plague transmission in Madagascar&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-09-17"></transaction-date>
   <value currency="GBP" value-date="2020-09-17">7668.29</value>
   <description>
    <narrative xml:lang="EN">Milestone 3 payment</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">University of Strathclyde, UK</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP2-01, &apos;Towards the production of &#x201C;Shigella plus&#x201D; a low-cost recombinant Shigella glycoconjugate vaccines&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-09-30"></transaction-date>
   <value currency="GBP" value-date="2020-09-30">-4980.35</value>
   <description>
    <narrative xml:lang="EN">Return of underspend</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">London School of Hygiene and Tropical Medicine, UK</narrative>
   </receiver-org>
  </transaction>
  <transaction ref="Catalyst project BVNCP3-24, &apos;SAL-O5_Asses the variation in lipopolysaccharide structure in circulating African invasive Salmonella Typhimurium isolates to predict vaccine coverage&apos;">
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-12-04"></transaction-date>
   <value currency="GBP" value-date="2020-12-04">-7238.27</value>
   <description>
    <narrative xml:lang="EN">Return of underspend</narrative>
   </description>
   <receiver-org>
    <narrative xml:lang="EN">University of Antwerp, Belgium</narrative>
   </receiver-org>
  </transaction>
 </iati-activity>
</iati-activities>
